» Articles » PMID: 11791159

Increased Visceral Fat Distribution in Drug-naive and Drug-free Patients with Schizophrenia

Overview
Date 2002 Jan 16
PMID 11791159
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate visceral fat distribution in patients with schizophrenia.

Design: Cross sectional study using CT scanning in patients with drug-naive and drug-free schizophrenia.

Subjects: Fifteen (13 men and two women) subjects with schizophrenia (mean age 33.7 y; mean body mass index (BMI)=26.7 kg/m(2)), and 15 age- and sex-matched controls (mean age 30.5 y; mean BMI=22.8 kg/(2)).

Measurements: Various fatness and fat distribution parameters (by CT scanning and anthropometry) and 16:00 h plasma cortisol.

Results: In comparison to controls, patients with schizophrenia had central obesity and had significantly higher levels of plasma cortisol. Furthermore, previous neuroleptic exposure did not appear to influence these findings as both drug-naive and drug-free patients had equally high levels of visceral fat deposition.

Conclusion: Central obesity is a well recognized risk factor in developing certain general medical conditions. This study shows that patients with schizophrenia have increased intra-abdominal fat which may provide one explanation for why they die prematurely.

Citing Articles

High Rates of Abnormal Glucose Metabolism Detected by 75 g Oral Glucose Tolerance Test in Major Psychiatric Patients with Normal HbA1c and Fasting Glucose Levels.

Yoshida S, Aizawa E, Ishihara N, Hattori K, Segawa K, Kunugi H Nutrients. 2025; 17(4).

PMID: 40004942 PMC: 11858036. DOI: 10.3390/nu17040613.


Pilot and Feasibility Studies of a Lifestyle Modification Program Based on the Health Belief Model to Prevent the Lifestyle-Related Diseases in Patients with Mental Illness.

Tsubata N, Kuroki A, Tsujimura H, Takamasu M, IIjima N, Okamoto T Healthcare (Basel). 2023; 11(12).

PMID: 37372808 PMC: 10298732. DOI: 10.3390/healthcare11121690.


Automatic Thoughts, Self-Stigma, and Resilience Among Schizophrenia Patients with Metabolic Syndrome: A Cross-Sectional Study.

Ma S, Ju P, Xia Q, Pan Z, Gao J, Zhang L Neuropsychiatr Dis Treat. 2023; 19:1195-1206.

PMID: 37220563 PMC: 10200106. DOI: 10.2147/NDT.S407662.


A Systematic Review on the Potential of Aspirin to Reduce Cardiovascular Risk in Schizophrenia.

Dao J, Saran S, Wang M, Michael C, Phan N, Bellon A Brain Sci. 2023; 13(2).

PMID: 36831911 PMC: 9954190. DOI: 10.3390/brainsci13020368.


Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.

Foiselle M, Barbosa S, Godin O, Wu C, Boukouaci W, Andre M Brain Behav Immun Health. 2022; 22:100436.

PMID: 35469211 PMC: 9034311. DOI: 10.1016/j.bbih.2022.100436.